Tissue microarray market seen reaching $23.6 billion by 2030

The tissue microarray market is projected to grow from $13.11 billion in 2025 to $23.61 billion by 2030, driven by cancer research, precision oncology and digital pathology adoption. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Tissue microarrays are becoming a bigger part of cancer research, biomarker validation and precision medicine workflows. - The market’s projected jump to $23.61 billion by 2030 signals sustained demand for high-throughput tissue analysis tools across research and diagnostics.

What happened: - The tissue microarray market is projected to rise from $13.11 billion in 2025 to $14.68 billion in 2026. - The market is forecast to reach $23.61 billion by 2030. - The forecast implies a 12.0% CAGR from 2025 to 2026 and a 12.6% CAGR from 2026 to 2030. - The report was published by The Business Research Company on Sept. 1, 2026. - A free sample of the market report is available. - The full tissue microarray market report is also available.

The details: - Historical growth was tied to cancer research, immunohistochemistry use, academic pathology activity, biomarker validation demand and wider availability of paraffin-embedded tissue specimens. - Future growth is expected to come from precision oncology investments, digital pathology adoption, translational research, multi-omics analysis and drug discovery use cases. - The report points to rising use of high-throughput tissue analysis systems, multiplex immunohistochemistry, standardized tissue arrays, automation in tissue microarray construction and integration with molecular diagnostics. - Tissue microarray is a high-throughput method for analyzing antigen expression across many tissue samples in one experiment, typically using paraffin blocks or formalin-fixed tissues. - The technique helps researchers evaluate protein expression across multiple specimens for pathology and clinical studies. - Personalized medicine is a major growth driver because tissue microarrays help speed biomarker assessment for patient-specific therapies. - In February 2024, the Personalized Medicine Coalition reported that the US FDA approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022. - North America held the largest share of the tissue microarray market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast reflects a broader shift toward more targeted treatment development and more standardized lab workflows. - Growth in digital pathology and molecular diagnostics suggests tissue microarrays are moving from a niche research tool to a more integrated platform in translational medicine.

What's next: - The market will likely track spending on precision oncology, research automation and multi-omics tools through 2030. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and updated graphics and tables. - More information is available from The Business Research Company at the company’s website. - The company also provided contact details for Saumya Sahay and listed LinkedIn, Facebook and X social channels.

The bottom line: - Tissue microarrays are positioned for strong growth as cancer research, personalized medicine and digital pathology continue to expand.